Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Plos One
|
December 15, 2010
A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis
Carlos Riveros, Drew Mellor, Kaushal S Gandhi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 14, 2024
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
Benjamin P Trewin, Russell C Dale, Jessica Qiu, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase
Tim Spelman, Sara Eichau, Raed Alroughani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 7, 2024
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
Yi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Neurology
|
August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Johannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Acta Neuropathologica Communications
|
September 5, 2019
Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
Fiona Tea, Joseph A Lopez, Sudarshini Ramanathan, et al.
JAMA Neurology
|
August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
Jordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network
Johannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Brain : a Journal of Neurology
|
July 13, 2016
Defining secondary progressive multiple sclerosis
Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Plos One
|
December 15, 2010
A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis
Carlos Riveros, Drew Mellor, Kaushal S Gandhi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 14, 2024
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
Benjamin P Trewin, Russell C Dale, Jessica Qiu, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase
Tim Spelman, Sara Eichau, Raed Alroughani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 7, 2024
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
Yi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Neurology
|
August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Johannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Acta Neuropathologica Communications
|
September 5, 2019
Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
Fiona Tea, Joseph A Lopez, Sudarshini Ramanathan, et al.
JAMA Neurology
|
August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
Jordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network
Johannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Brain : a Journal of Neurology
|
July 13, 2016
Defining secondary progressive multiple sclerosis
Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Page
of 5